Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. The company operates through a network of subsidiaries and partner companies, including Journey Medical Corporation, Mustang Bio, Avenue Therapeutics, Cellvation, Cyprium Therapeutics, Helocyte, Oncogenuity, and Urica Therapeutics. Its portfolio spans dermatology, oncology, rare diseases, and gene therapy, with approved products including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend, UNLOXCYT, and ZYCUBO. Fortress maintains partnerships with academic institutions and pharmaceutical companies such as City of Hope, Dana-Farber Cancer Institute, Columbia University, the University of Pennsylvania, AstraZeneca, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Sentynl Therapeutics, Axsome Therapeutics, and Duke University. The company generates revenue through product sales, equity holdings, dividends, and royalties, and has executed strategic transactions involving the sale of Checkpoint Therapeutics to Sun Pharma and Baergic Bio to Axsome.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage fortressbiotech.com
Sector Healthcare IR page fortressbiotech.com/investors
Tags
dermatology, oncology, rare diseases, gene therapy, biopharmaceuticals, drug development, pharmaceutical licensing, royalty streams, clinical trials, fda approved products, Journey Medical Corporation, Mustang Bio, Avenue Therapeutics, Cellvation, Cyprium Therapeutics, Helocyte, Oncogenuity, Urica Therapeutics, Checkpoint Therapeutics, Baergic Bio, Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend, UNLOXCYT, ZYCUBO, CUTX-101, ATX-04, DFD-29, cosibelimab-ipdl, copper histidinate, clenbuterol, minocycline hydrochloride, isotretinoin, doxycycline, City of Hope, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Columbia University, University of Pennsylvania, AstraZeneca, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Sentynl Therapeutics, Axsome Therapeutics, Duke University
Press page fortressbiotech.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 71.669M
Market cap (USD) $ 71.669M
P/E 0.91
PEG —
P/BV 0.45
P/S 1.04
P/OCF 0.57
P/FCF -1.09
Dividend yield —
Turnover / mcap —
Returns  
ROE 18.8%
ROI 6.7%
ROIC -51.5%
Profit margin 11.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 21.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 61.239M 55.134M 59.662M 70.995M 63.134M 44.531M 34.921M 23.376M 187.584M 16.48M 863K — — — — —
Net profit 6.815M -45.997M -60.637M -86.575M -64.703M -46.526M -39.96M -84.147M -66.876M -55.095M -48.428M -20.386M -37.158M -27.61M -36.36M -9.982M
Free cash flow -65.777M -80.191M -128.288M -182.116M -121.106M -85.608M -97.306M -105.93M -87.51M -52.183M -20.661M -16.334M -29.686M — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 3.66 2.03 3.01 0.66 2.5 3.17 2.57 0.86 3.99 2.7 2.79 — — — — —
Price performance 12m 0.81 -0.33 3.6 -0.74 -0.21 0.23 1.99 -0.78 0.48 -0.03 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.83M 7.76M 5.5M 13.5M 19.3M 23.1M 28.2M 15.2M 10.2M 29.8M
↳ YoY growth +323.9% -29.1% +146.3% +42.9% +19.4% +22.0% -46.0% -32.8% +191.1%
↳ 5y CAGR +66.1% +29.5% +22.6% -5.4% +9.0%
Lease liabilities (USD) — — 0.00 25.5M 24.7M 23.1M 24M 20.8M 17.4M 14.8M
Cash and deposits (USD) 88.3M 114M 65.5M 137M 233M 306M 178M 80.9M 57.3M 79.4M
Intangible assets (USD) 17.4M 15.2M 1.42M 7.38M 14.6M 12.6M 27.2M 20.3M 31.9M 27.6M
Right-of-use assets (USD) — — 0.00 21.5M 20.5M 19M 20M 17M 13.9M 12.3M
Cash flow detail
Operating cash flow (USD) -45.8M -85.4M -98.8M -95M -83.7M -117M -179M -128M -80.2M -65.8M
Purchases of property, plant and equipment (USD) -6.37M -2.08M -7.08M -2.35M -1.93M -4.57M -2.72M -63,000 0.00 —
Purchases of intangible assets (USD) -350,000 0.00 -1.2M -2.4M -1.2M -400,000 0.00 -5M -15M 0.00
Change in receivables (cash effect) (USD) -1.83M -5.93M 2.26M -8.14M -5.86M 768,000 -5.38M 12.6M 4.48M -19.3M
Change in inventories (cash effect) (USD) -203,000 32,000 -507,000 -179,000 -547,000 -8.46M 1.74M 3.95M -4.23M 4.81M
Change in payables (cash effect) (USD) 5.4M 9.73M 4.69M 2.1M 6.52M 43.3M 8.35M -24.4M -6.39M -7.97M
Dividends paid (cash effect) (USD) — — — 0.00 -237,000 -749,000 -749,000 -736,000 -694,000 -664,000
Share buybacks (cash effect) (USD) — — — 0.00 -70,000 — — — — —
Interest paid (cash effect) (USD) -349,000 -207,000 -4.45M -5.44M -8.2M -6.92M -9.42M -7.95M -7.16M -7.39M
Income taxes paid (cash effect) (USD) — — — — — -993,000 -858,000 55,000 -120,000 -49,000
Share-based compensation (USD) 12.1M 14M 15M 13.2M 13.5M 19.5M 23M 17M 32.6M 28.7M
Operating cash flow before change in receivables (USD) -44M -79.5M -101M -86.8M -77.8M -117M -174M -141M -84.7M -46.4M
Free cash flow (OCF - PPE - intangibles) (USD) -52.5M -87.5M -107M -99.7M -86.8M -122M -182M -133M -95.2M —
Income detail
Research and development expense (USD) -35.1M 52.5M 83.3M 81.3M 64.1M 129M 135M 106M 56.6M 11.9M
↳ 5y CAGR +24.6% +26.5% +51.4% +28.4% +20.8% +4.9% -7.0% -28.6%
Provision for credit losses (USD) — — 0.00 100,000 49,000 48,000 284,000 435,000 516,000 -211,000
Credit cost ratio (credit losses / average receivables) (%) — — 0.0% 1.1% 0.3% 0.2% 1.1% 2.0% 4.1% 1.1%
Reported Mar 16, 2017 Mar 18, 2019 Mar 16, 2020 Mar 31, 2021 Mar 31, 2021 Mar 28, 2022 Mar 31, 2023 Mar 28, 2024 Mar 31, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025

Fortress repaid its credit facility in full in September 2026

A subsidiary of Fortress entered into a license agreement for FB-607, which is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 2 study to assess the safety and efficacy in patients with irritable bowel syndrome with diarrhea

Partnered programs continue to advance, with Crystalys Therapeutics closing a $130 million Series B financing, and royalties generated from ZYCUBO® and UNLOXCYT™

Miami, FL – November 13, 2026 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2026.

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “The third quarter of 2026 reflected continued execution across our diversified portfolio.

Download as PDF November 05, 2026

Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET

SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2026 financial results after the U.S. financial markets close on Thursday, November 12, 2026. Journey Medical management will conduct a conference call and audio webcast on Thursday, November 12, 2026 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10213114/1052fc6b3ac . Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com , and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com .

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
[email protected]

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]   

Primary Logo

Source: Journey Medical Corporation

Released November 5, 2026

Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

© 2026 Fortress Biotech, Inc. All Rights Reserved.

Facebook Twitter Linkedin

Accessibility Statement Privacy Policy Disclaimer Sitemap

Fortress Biotech, Inc. — Other Events Bull 2 Bear 0 Financing

As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “Company”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “Oaktree Agreement”) with Oaktree Fund Administration, LLC and the lenders from time-to-time party thereto. On September 30, 2026, the Company repaid in full the remaining $15.0 million in outstanding principal under the facility, together with approximately $435,000 in accrued interest, a prepayment fee of $150,000 and other closing costs. Upon such repayment, all indebtedness under the Oaktree Agreement was deemed satisfied and paid in full, all liens and other security interests in the Company’s property securing the indebtedness under the Oaktree Agreement were released and terminated and the Oaktree Agreement automatically terminated pursuant to its terms.

Prompts

Fortress Biotech, Inc. (ticker FBIO), listed in United States.

Company History

Date Change Detail
Apr 30, 2015 Renamed CORONADO BIOSCIENCES INC → FORTRESS BIOTECH, INC.

ETFs Holding Fortress Biotech, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 2,971 $ 5,080.41 Nov 16, 2026
BSVO 0.00% 25,000 $ 50K Nov 18, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
FBIO canonical Common share — US nasdaq 2.14 USD 2026-09-30
FBIOP Preferred — US nasdaq — —